



EACR sponsored

03.12.2021. Virtual event 09.00 – 17.30

SDIR5 CONGRESS PROGRAMME

- 09.00 – 09.05 **Congress welcome and opening.** SDIR President Mirjana Branković–Magić
09.05 – 09.30 EACR Plenary lecture – EACR President Caroline Dive. **Liquid biopsies in lung cancer.** *University of Manchester, Manchester, UK*
09.30 – 09.40 Discussion
- 09.40 – 11.05 **Session: Advances in solid tumor research**
Chairs: Caroline Dive and Milena Čavić
- 09.40 – 10.00 Remond J.A. Fijneman. **ctDNA biomarker detection in patients with colorectal cancer.** *The Netherlands Cancer Institute, Amsterdam, Netherlands*
10.00 – 10.20 Gunes Esendagli. **Mesenchymal properties and immune checkpoint pathways in small cell lung cancer (SCLC) stem cells.** *Hacettepe University Cancer Institute, Ankara, Turkey*
10.20 – 10.50 **Short talks selected from SDIR member PIs of The Program for Excellent Projects of Young Researchers (PROMIS) of the Science Fund of the Republic of Serbia**
10.20 – 10.30 Miljana Tanić. **Tracking systemic therapy resistance of lung and colorectal cancer through targeted NGS analysis of genetic and epigenetic variants in liquid biopsies.** *Institute of Oncology and Radiology of Serbia, Serbia*
10.30 – 10.40 Aleksandra Nikolić. **Cancer biosensors based on gene regulatory elements.** *Institute of Molecular Genetics and Genetic Engineering, Serbia*
10.40 – 10.50 Jelena Grahovac. **Drug repurposing in pancreatic ductal adenocarcinoma.** *Institute of Oncology and Radiology of Serbia, Serbia*
10.50 – 11.05 Discussion
11.05 – 11.15 Break
- 11.15 – 12.40 **Session: Cancer and metabolism**
Chair: Milica Pešić
- 11.15 – 11.35 Liang Li. **An antibody drug conjugate–like agent DTLL sensitizes gemcitabine efficacy in pancreatic cancer based on SMAD4 profiles** *Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*

- 11.35 – 11.55 Ljubica Harhaji–Trajković. **Dual targeting of energy metabolism and lysosomes as an anticancer strategy; it is not all about autophagy.** *Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia*
- 11.55 – 12.23 Short talks selected from abstracts
- 11.55 – 12.02 Nikolina Piteša. **Genes for competing endogenous RNAs as targets of transcription factors GLI in melanoma cell lines.** *Ruđer Bošković Institute, Zagreb, Croatia*
- 12.02 – 12.09 Cristina P.R. Xavier. **Chitinase 3–like–1 (CHI3L1) as a potential therapeutic target for pancreatic cancer.** *Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Institute of Molecular Pathology and Immunology, University of Porto, Portugal*
- 12.09 – 12.16 Jovana Jagodić. **Elemental profile of glioblastomas – analysis of blood, cerebrospinal fluid and brain tissue.** *Faculty of Chemistry, Belgrade, Serbia*
- 12.16 – 12.23 Stefana Stojanović. **Hsa–miR–222 identifies high–risk PTC patients with classical variant architecture.** *Institute for the Application of Nuclear Energy – INEP, University of Belgrade, Belgrade, Serbia*
- 12.23 – 12.40 Discussion
- 12.40 – 12.45 Break
- 12.45 – 14.30 **Session: Radiobiology**
Chairs: Marina Nikitović, Tatjana Stanojković and Ivana Matić
- 12.45 – 13.00 Irina Besu Žižak. **The role of IL6 in radiotherapy–induced toxicity.** *Institute of Oncology and Radiology of Serbia, Serbia*
- 13.00 – 13.15 Bojana Ilić. **Cellular senescence in ionizing radiation.** *Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Serbia*
- 13.15 – 13.30 Jadranka Antić. **Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications.** *Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia*
- 13.30 – 13.45 Sercan Ergün. **The interrelationship between FYN and miR–128/193a–5p/494 in Imatinib resistance in prostate cancer.** *Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey*
- 13.45 – 14.13 Short talks selected from abstracts
- 13.45 – 13.52 Sami Ahmad. **Gene expression kinetics and pathway analysis of skin fibroblasts irradiated *in vitro*.** *Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany*
- 13.52 – 13.59 Jelena Stanić. **Radiation–induced lymphocyte apoptosis as a possible biological predictor of radiotherapy toxicity in prostate cancer patients.** *Institute of Oncology and Radiology of Serbia, Serbia*
- 13.59 – 14.06 Aleksandar Stepanović. **Can miRNA expression patterns predict radiotoxicity in patients with glioblastoma?** *Institute of Oncology and Radiology of Serbia, Serbia*
- 14.06 – 14.13 Bojana Kožik. **Potential predictive role of K–ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with**

- neoadjuvant chemoradiotherapy.** *Vinča Institute of Nuclear Sciences, National Institute of Republic of Serbia, University of Belgrade, Serbia*
- 14.13 – 14.30 Discussion
- 14.30 – 15.15 **Poster Session, lunch break and industry session viewing**
Moderator: Ana Krivokuća
- 15.15 – 17.00 **Session: Imaging in cancer**
Chair: Jelena Grahovac
- 15.15 – 15.35 Bojana Gligorijević. **Real-time microscopy of invasive cancer cells in the tumor microenvironment context.** *Temple University, USA*
- 15.35 – 15.55 Jelena Stanisavljević. **Defining and imaging colon cancer heterogeneity.** *The Institute of Photonic Sciences, Barcelona Institute for Science and Technology, Spain*
- 15.55 – 16.15 Giorgio Seano. **Vessel co-option and resistance to therapy in glioblastoma.** *Institut Curie Research Center, Centre Universitaire, France*
- 16.15 – 16.43 Short talks selected from abstracts
- 16.15 – 16.22 Predrag Jovanovic. **Characterizing the role of 4E-BP1 in breast cancer metastasis.** *Jewish General Hospital, Lady Davis Institute, Montreal, Canada;*
McGill University, Experimental Medicine, Montreal, Canada
- 16.22 – 16.29 F. Koutsougianni. **Siramesine, a non-opioid σ_2 receptor agonist as a potential agent for the development of novel targeted treatments for pancreatic cancer.** *University of Thessaly, Larisa, Greece*
- 16.29 – 16.36 Batuhan Mert Kalkan. **The role of Nek2 on centrosome clustering in cancer cells with extra centrosomes.** *Koç University, Graduate School of Health Sciences, Istanbul, Turkey*
- 16.36 – 16.43 Tijana Martinov. **Sox2-targeted T cell therapy for treating multiple myeloma.** *Fred Hutchinson Cancer Research Center, Seattle, United States of America*
- 16.43 – 17.00 Discussion
- 17.00 – 17.30 **Closing remarks and Best abstract awards.** SDIR President Mirjana Branković-Magić